M W Jann

Summary

Affiliation: Mercer University
Country: USA

Publications

  1. ncbi Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers
    Scott R Penzak
    Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia, USA
    J Clin Psychopharmacol 22:366-70. 2002
  2. ncbi Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers
    Michael W Jann
    Department of Clinical and Administrative Sciences, Mercer University, Southern School of Pharmacy, Atlanta, Georgia 30341, USA
    Pharmacotherapy 26:627-33. 2006
  3. ncbi Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir
    Michael W Jann
    Mercer University College of Pharmacy and Health Sciences, 3001 Mercer University Dr, Atlanta, GA 30341, USA
    Eur J Clin Pharmacol 68:715-21. 2012
  4. ncbi Advanced strategies for treatment of Parkinson's disease: the role of early treatment
    Michael W Jann
    Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA, USA
    Am J Manag Care 17:S315-21. 2011
  5. ncbi Antidepressant agents for the treatment of chronic pain and depression
    Michael W Jann
    Department of Pharmacy Practice, Mercer University College of Pharmacy and Health Sciences, 3001 Mercer University Drive, Atlanta, GA 30341, USA
    Pharmacotherapy 27:1571-87. 2007
  6. ncbi Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis
    Michael W Jann
    Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, Atlanta, Georgia 30341, USA
    Pharmacotherapy 24:1759-83. 2004
  7. ncbi Clinical significance of drug binding, protein binding, and binding displacement drug interactions
    Michael W Jann
    Departments of Clinical and Administratives Sciences, Mercer University, Atlanta, Georgia, USA
    Psychopharmacol Bull 36:22-41. 2002
  8. ncbi Pharmacology and clinical efficacy of cholinesterase inhibitors
    M W Jann
    Pharmacy Practice and Pharmaceutical Sciences, Mercer University Southern School of Pharmacy, Atlanta, GA 30341, USA
    Am J Health Syst Pharm 55:S22-5. 1998
  9. ncbi Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
    Michael W Jann
    Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, Atlanta, Georgia 30341, USA
    Clin Pharmacokinet 41:719-39. 2002
  10. ncbi Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype
    Michael W Jan
    Department of Pharmacy Practice and Pharmaceutical Sciences, Mercer University, Southern School of Pharmacy, Atlanta, GA 30341, USA
    Drug Metabol Drug Interact 19:1-11. 2002

Collaborators

Detail Information

Publications17

  1. ncbi Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers
    Scott R Penzak
    Department of Pharmacy Practice, Mercer University, Southern School of Pharmacy, Atlanta, Georgia, USA
    J Clin Psychopharmacol 22:366-70. 2002
    ..001) after ritonavir. Ritonavir significantly reduced the systemic exposure of olanzapine in volunteers. Patients receiving this combination may ultimately require higher olanzapine doses to achieve desired therapeutic effects...
  2. ncbi Lack of pharmacokinetic interaction between lamotrigine and olanzapine in healthy volunteers
    Michael W Jann
    Department of Clinical and Administrative Sciences, Mercer University, Southern School of Pharmacy, Atlanta, Georgia 30341, USA
    Pharmacotherapy 26:627-33. 2006
    ..When prescribing high doses of olanzapine and lamotrigine for bipolar disorder, patients must be carefully monitored...
  3. ncbi Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir
    Michael W Jann
    Mercer University College of Pharmacy and Health Sciences, 3001 Mercer University Dr, Atlanta, GA 30341, USA
    Eur J Clin Pharmacol 68:715-21. 2012
    ..To assess the effects of venlafaxine extended-release (XR) capsules and desvenlafaxine extended-release (XR) tablets upon indinavir pharmacokinetic properties when co-administrated to healthy volunteers...
  4. ncbi Advanced strategies for treatment of Parkinson's disease: the role of early treatment
    Michael W Jann
    Department of Pharmacy Practice, College of Pharmacy and Health Sciences, Mercer University, Atlanta, GA, USA
    Am J Manag Care 17:S315-21. 2011
    ..It appears that early treatment with the MAO-B inhibitor rasagiline (1 mg), as compared with late treatment, delays the onset of worsened UPDRS score, especially the nonmotor activities of daily living subscore...
  5. ncbi Antidepressant agents for the treatment of chronic pain and depression
    Michael W Jann
    Department of Pharmacy Practice, Mercer University College of Pharmacy and Health Sciences, 3001 Mercer University Drive, Atlanta, GA 30341, USA
    Pharmacotherapy 27:1571-87. 2007
    ..Their extended use into chronic pain, depression with physical pain, physical pain with or without depression, and other potential medical conditions should be recognized...
  6. ncbi Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis
    Michael W Jann
    Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, Atlanta, Georgia 30341, USA
    Pharmacotherapy 24:1759-83. 2004
    ..A neurodevelopmental model of cognitive impairment in schizophrenia aids in understanding why atypical antipsychotics improve cognitive symptoms...
  7. ncbi Clinical significance of drug binding, protein binding, and binding displacement drug interactions
    Michael W Jann
    Departments of Clinical and Administratives Sciences, Mercer University, Atlanta, Georgia, USA
    Psychopharmacol Bull 36:22-41. 2002
    ..Additional studies are needed to examine the optimal methods for switching patients from one atypical agent to another atypical antipsychotic...
  8. ncbi Pharmacology and clinical efficacy of cholinesterase inhibitors
    M W Jann
    Pharmacy Practice and Pharmaceutical Sciences, Mercer University Southern School of Pharmacy, Atlanta, GA 30341, USA
    Am J Health Syst Pharm 55:S22-5. 1998
    ..Although ChEIs generally improve cognition in patients with AD, differences among these medications are substantial in some cases and should be thoroughly considered by clinicians...
  9. ncbi Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
    Michael W Jann
    Department of Clinical and Administrative Sciences, Southern School of Pharmacy, Mercer University, Atlanta, Georgia 30341, USA
    Clin Pharmacokinet 41:719-39. 2002
    ..The increased information available to clinicians can optimise the use of these agents in the management of patients with Alzheimer's disease...
  10. ncbi Pharmacokinetics of fluvoxamine in relation to CYP2C19 phenotype and genotype
    Michael W Jan
    Department of Pharmacy Practice and Pharmaceutical Sciences, Mercer University, Southern School of Pharmacy, Atlanta, GA 30341, USA
    Drug Metabol Drug Interact 19:1-11. 2002
    ..To evaluate the pharmacokinetics of fluvoxamine (FLV) in poor metabolizers (PMs) versus extensive metabolizers (EMs) of cytochrome P450 (CYP)2C19...
  11. ncbi Effect of thioridazine on gap junction intercellular communication in connexin 43-expressing cells
    D F Matesic
    Southern School of Pharmacy, Mercer University, Atlanta, Georgia, USA
    Cell Biol Toxicol 22:257-68. 2006
    ....
  12. ncbi Altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism
    Yuen Yi Hon
    Department of Clinical and Administrative Sciences, Mercer University Southern School of Pharmacy, Atlanta, Georgia, USA
    J Clin Pharmacol 46:408-17. 2006
    ..031 and .033, respectively, Wilcoxon rank sum test). Subjects who are heterozygous for the T314 variant allele thus appeared less sensitive to the suppressive effects of methylprednisolone on cortisol secretion...
  13. ncbi Disposition of D-serine in healthy adults
    Guochuan E Tsai
    Department of Psychiatry, Harbor-UCLA Medical Center, F9, 1000 W. Carson Street, Torrance, CA 90509, USA
    J Clin Pharmacol 48:524-7. 2008
  14. ncbi Dosing strategies of clozapine-fluvoxamine cotreatment
    Mong-Liang Lu
    J Clin Psychopharmacol 22:626-8. 2002
  15. ncbi Dose-dependent alternations in the pharmacokinetics of olanzapine during coadministration of fluvoxamine in patients with schizophrenia
    Chih-Chiang Chiu
    Laboratory of Biological Psychiatry, Taipei City Psychiatric Center, Taipei, Taiwan
    J Clin Pharmacol 44:1385-90. 2004
    ..Presumably, altered olanzapine pharmacokinetics are attributed to the inhibition of CYP1A2. Patients treated with the combination of olanzapine and fluvoxamine should be monitored carefully...
  16. ncbi Correlation of cytochrome P450 (CYP) 1A2 activity using caffeine phenotyping and olanzapine disposition in healthy volunteers
    Kara Lee Shirley
    Albany College of Pharmacy, Albany, NY, USA
    Neuropsychopharmacology 28:961-6. 2003
    ..Interpatient variability in CYP1A2 activity may explain the wide interpatient variability in olanzapine disposition. Compounds that modulate CYP1A2 activity may be expected to alter olanzapine pharmacokinetics accordingly...
  17. ncbi Endogenous histamine and cortisol levels in subjects with different histamine N-methyltransferase C314T genotypes : a pilot study
    Yuen Yi Hon
    Department of Clinical and Administrative Sciences, Mercer University Southern School of Pharmacy, Atlanta, Georgia, USA
    Mol Diagn Ther 10:109-14. 2006
    ....